摘要
目的:探讨不同年龄段地中海贫血患儿接受造血干细胞移植后疗效的差异。方法:回顾性分析我科收治的地中海贫血患儿临床资料,以5岁为界,分为2-5岁组和6-12岁组,比较两组患儿植入成功率、移植相关死亡率、GVHD发生率和其他移植相关并发症差异,以及无地中海贫血生存率差异。结果:2-5岁组移植后GVHD发生率、出血性膀胱炎和重度口腔黏膜炎发生率均显著低于6-12岁组,两组无地中海贫血生存率比较差异无统计学意义。结论:低年龄组(2-5岁)患儿移植后并发症少,生存质量高,选择2-5岁之间进行干细胞移植更利于患儿的康复。
Objective: To investigate the difference of therapeutic effects on children with thalassemia at different age after hematopoietic stem cell transplantation. Methods: The clinical data of children with thalassemia treated in our hospital were retrospectively analyzed. The children were divided into 2-5 years old group and 6-12 years old group. The success rate of implantation, transplant-related mortality, GVHD incidence, and other transplant-related complications, as well as thalassemia-free survival(TFS) were compared between the two groups. Results: The incidence of GVHD, hemorrhagic cystitis and severe oral mucositis after transplantation in the 2-5 years old group were significantly lower than those in the 6-12 years old group, while there was no statistically significant difference in the TFS between the two groups. Conclusion: Children in the low age(2-5 years old) group show fewer complications and higher quality of life after transplantation, therefore, stem cell transplantation at 2-5 years old is more conducive to rehabilitation of the children with thalassemia.
作者
康栋梁
谭永红
陈亚玫
陆婧媛
石洁
颜秀珍
鹿全意
KANG Dong-Liang;TAN Yong-Hong;CHEN Ya-Mei;LU Jing-Yuan;SHI Jie;YAN Xiu-Zhen;LU Quan-Y(Quanzhou First Hospital Affiliated to Fujian Medical Universiy,Quanzhou 362000,Fuian Province,China;The School of Clinical Medicine Fujian Medical University,Fuzhou 350122 Fujian Province,China;Department of Hematology Zhongshan Hospital Xiamen University,Xiamen 361004,Fujian Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2022年第2期539-542,共4页
Journal of Experimental Hematology
基金
厦门市医疗卫生指导项目(编号:3502Z20209024)。
关键词
异基因造血干细胞移植
地中海贫血
年龄
并发症
疗效
allogeneic hematopoietic stem cell transplantation
thalassemia
age
complication
efficacy
